Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  BioMérieux       FR0010096479

BIOMÉRIEUX
My previous session
Most popular
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

BIOMERIEUX : Detection of Schmallenberg virus made possible by bioMérieux: the ADIAGENE PCR kit has been validated by ANSES

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/28/2012 | 12:50pm EST

Detection of Schmallenberg virus made possible by bioMérieux: the ADIAGENE PCR kit has been validated by ANSES

Marcy l'Etoile, France - March 27, 2012. ADIAGENE, a member of the bioMérieux group and specialized in diagnostics for animal health, has obtained ANSES validation for a kit for the detection of Schmallenberg virus, responsible for the epidemic currently affecting livestock in Europe. Based on molecular biology techniques, the new ADIAVET™ Schmallenberg virus PCR detection kit was developed by ADIAGENE in close collaboration with the French Agency for Food, Environmental and Occupational Health and Safety (ANSES, Maisons-Alfort, France). The Direction Générale de l'Alimentation (DGAL) has just authorized its use in certified French public veterinary laboratories.

distributed by

This press release was issued by BioMérieux SA and was initially posted at http://www.biomerieux.com/servlet/srt/bio/portail/dynPage?open=PRT_NWS_REL&doc=PRT_NWS_REL_G_PRS_RLS _269 . It was distributed, unedited and unaltered, by noodls on 2012-03-28 18:43:26 PM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOMÉRIEUX
2018BIOMERIEUX : bioMérieux lance les panels Pneumonie BIOFIRE® FILMARRAY® suite à l..
PU
2018BIOMERIEUX : bioMérieux acquires a majority stake in Hybiomeand strengthens its ..
PU
2018BIOMERIEUX : bioMérieux acquires a majority stake in Hybiome and strengthens its..
PU
2018BIOMERIEUX : bioMérieux acquiert la majorité du capital de Hybiome et renforce a..
PU
2018BIOMÉRIEUX : 3rd quarter results
CO
2018STRATEGY : Has being defensive paid off since the 2008 crisis?
2018BIOMERIEUX SA : quaterly sales release
2018BIOMERIEUX : bioMérieux commitments in the CDC's “AMR Challenge”, a ..
PU
2018EUROPE : European shares dip on trade tensions, Italy banks buoyed
RE
2018BIOMERIEUX : First-Half 2018 Results
PU
More news
Financials (€)
Sales 2018 2 405 M
EBIT 2018 339 M
Net income 2018 238 M
Debt 2018 143 M
Yield 2018 0,65%
P/E ratio 2018 29,81
P/E ratio 2019 27,20
EV / Sales 2018 3,07x
EV / Sales 2019 2,79x
Capitalization 7 244 M
Chart BIOMÉRIEUX
Duration : Period :
bioMérieux Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 12
Average target price 67,3 €
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Alexandre Mérieux Chairman & Chief Executive Officer
Guillaume Bouhours Chief Financial Officer & Executive Vice President
Mark Miller Chief Medical Officer
Jean-Luc Bélingard Director
Michele Palladino Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOMÉRIEUX48.06%8 235
BIOMÉRIEUX6.43%8 235
DIASORIN13.22%5 092
AUTOBIO DIAGNOSTICS CO LTD7.10%3 240
SIEGFRIED HOLDING AG3.27%1 480
MACCURA BIOTECHNOLOGY CO LTD--.--%1 205